How CVS Health Makes its Money: Revenue Breakdown

How Does CVS Health Make its Money?

CVS Health is an integrated healthcare company and the largest pharmacy and health services provider in the United States. Through its three primary segments, CVS combines a nationwide pharmacy chain, a pharmacy benefits manager (Caremark), and a major health insurance plan (Aetna). This vertically integrated model allows CVS to touch nearly every part of the healthcare delivery chain — from prescribing and dispensing drugs to managing pharmacy benefits and providing health insurance coverage.

The logic behind CVS’s integration strategy is that controlling pharmacy dispensing, benefit management, and insurance under one roof creates data advantages and cost efficiencies that standalone competitors cannot match. In practice, however, the model has faced growing scrutiny. The Aetna insurance segment has been hit by rising medical costs, the PBM business faces potential regulation around drug pricing transparency, and the retail pharmacy footprint is shrinking as consumer traffic shifts online. New CEO David Joyner, who took over in late 2024, is navigating all three challenges simultaneously.

CVS Health (CVS) Business Model

CVS Health Competitors

CVS Health’s key competitors and comparable public companies in the healthcare sector include UnitedHealth Group, Eli Lilly, Pfizer, and Walmart. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how CVS Health stacks up by comparing their revenue breakdown, margins, and growth metrics.

Revenue Breakdown

Health Services (Caremark PBM) — 49% of Revenue

Caremark is the largest segment by revenue and one of the three biggest pharmacy benefits managers in the U.S. alongside Express Scripts (Cigna) and OptumRx (UnitedHealth). PBMs act as intermediaries between drug manufacturers, insurers, and pharmacies — negotiating rebates, determining which drugs appear on formularies, and processing prescription claims. Caremark manages pharmacy benefits for employers, health plans, and government programs covering over 110 million members.

Revenue growth of 3.5% in 2024 was driven by increased prescription volume and specialty pharmacy growth, partially offset by client pricing pressure. The PBM model has come under intense political scrutiny, with bipartisan proposals in Congress to ban or restrict the rebate system that PBMs use to negotiate drug prices. If pass-through pricing becomes mandated, it would fundamentally change Caremark’s profit model — shifting revenue from opaque rebate spreads to transparent administrative fees.

Health Care Benefits (Aetna) — 30% of Revenue

Aetna is CVS’s health insurance segment, acquired for $69 billion in 2018. The unit provides medical, pharmacy, dental, and behavioral health plans to employers, individuals, and government programs including Medicare Advantage and Medicaid. Aetna insures roughly 26 million medical members and the revenue growth of 5.6% in 2024 reflected Medicare Advantage enrollment gains and premium increases.

However, Aetna has been the most troubled segment. The medical benefit ratio (MBR) — the percentage of premiums paid out as medical claims — increased sharply in 2024 as healthcare utilization surged post-COVID. Rising costs from GLP-1 weight loss drugs like Wegovy and Zepbound have put additional pressure on medical costs across the insurance industry. CVS took significant reserve charges in the Aetna segment, and the unit’s profitability deteriorated meaningfully year-over-year, prompting the CEO change in late 2024.

Pharmacy & Consumer Wellness — 35% of Revenue

This segment operates roughly 9,000 CVS pharmacy locations (down from over 10,000 in recent years after store closures), the CVS.com e-commerce site, and the MinuteClinic walk-in health clinics. Revenue comes from prescription dispensing (the vast majority), front-store product sales (health, beauty, convenience items), and clinical services including vaccinations and health screenings. The segment grew 5.4% in 2024, driven by prescription volume growth, specialty pharmacy, and COVID/flu vaccination revenue.

The retail pharmacy business faces structural headwinds. Reimbursement rates from insurers and PBMs continue to decline, squeezing pharmacy margins. Front-store traffic has eroded as consumers shift to Amazon, dollar stores, and grocery pharmacy counters. CVS has responded by closing hundreds of underperforming locations and investing in health services — positioning stores as healthcare destinations with MinuteClinic, HealthHUB services, and chronic disease management programs rather than traditional drugstores.

CVS Health (CVS) Income Statement

All values in millions USD unless otherwise stated.

Financial data sourced from CVS Health SEC Filings.

CVS Health (CVS) Key Financial Metrics

• Gross Margin: 12.7%
• Operating Margin: 2.9%
• Revenue Growth: 5.1%

Is CVS Health Profitable?

Yes, CVS Health is profitable, but the margins are razor-thin and under pressure. The 2.9% operating margin reflects the nature of health insurance and pharmacy retail — both are high-volume, low-margin businesses. CVS’s 12.7% gross margin is actually healthy for the healthcare services industry, but the gap between gross and operating margin shows how much of that goes to operating costs including running 9,000 stores, claims processing, and a massive workforce. Net income of $4.6 billion sounds large in absolute terms, but on $357.8 billion of revenue, it represents a net margin of just 1.3%. The Aetna segment’s deteriorating medical cost ratio was the primary drag on profitability in 2024, and the company’s ability to reprice insurance plans and manage utilization trends will determine whether margins stabilize.

CVS Health (CVS): What to Watch

1. Aetna medical benefit ratio — Rising healthcare utilization and GLP-1 drug costs drove the MBR above targets in 2024. If CVS can’t bring this ratio back in line through premium increases and cost management, Aetna’s profitability problems will overshadow the rest of the business.
2. PBM regulatory risk — Congressional proposals to ban PBM rebate spreads and require pass-through pricing could eliminate a key Caremark profit mechanism. The FTC has also launched investigations into PBM practices, adding uncertainty.
3. Store footprint optimization — CVS is closing hundreds of locations but still operates the largest pharmacy chain in the U.S. The balance between cutting costs and maintaining accessibility and convenience will be critical.
4. GLP-1 impact across segments — GLP-1 weight loss and diabetes drugs affect CVS in multiple ways: increased pharmacy dispensing revenue, higher insurance claims costs at Aetna, and complex PBM negotiations with manufacturers like Novo Nordisk and Eli Lilly.
5. New CEO execution — David Joyner, previously head of Caremark, took over as CEO in late 2024 after the board ousted Karen Lynch. His turnaround plan and ability to stabilize the Aetna segment while growing health services will define CVS’s trajectory.

CVS Health (CVS) Financial Summary

CVS Health remains the largest integrated healthcare company in the U.S. with $357.8 billion in revenue, but the integration thesis has been under strain. The Aetna insurance segment faces rising medical costs that compressed profitability in 2024, Caremark’s PBM model confronts growing regulatory scrutiny, and the retail pharmacy footprint is shrinking. Despite these challenges, the sheer scale of CVS — touching 110+ million PBM members, 26 million insured lives, and 9,000 pharmacy locations — gives it negotiating leverage that few competitors can match. Net income of $4.6 billion and the 2.9% operating margin reflect a business generating significant absolute profits on thin margins, but investors are watching closely to see if new CEO David Joyner can restore earnings momentum.